blood taking
PreclinicalBiologic
blood taking is one of 7 biologic programs targeting Aortic Aneurysm. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
6 competitors in Aortic Aneurysm
#DrugCompanyPhaseTrials
1Diamox
TevaApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cleviprex
Chiesi Farmaceutici S.p.A.Preclinical
Sufenta
LLeaf Vertical Inc.
Preclinical
Definity
MMicrovascular Therapeutics, LLC
Preclinical
blood taking
CCentre Hospitalier Universitaire de Besancon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Aortic Aneurysm1 trial
Follow up of Patients With Aortic Aneurysm by Dosage of Circulant Endothelial Progenitor Cells
Unknown status·—·N/A·NCT02919709·40 enrolled
Diagnosis1 trial
Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis
Recruiting·—·N/A·NCT05824442·43 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for blood taking. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details